https://www.selleckchem.com/products/mmaf.html
Adjuvant ( ) tyrosine kinase inhibitors (TKIs) are increasing considered for the tailored management of resectable non-small cell lung cancer (NSCLC). This study aimed to analyze the survival and toxicity profile of patients with mutation-positive NSCLC treated with adjuvant icotinib. This was a single-center retrospective study of patients with mutation-positive NSCLC who underwent R0 (microscopically margin-negative) resection and received adjuvant icotinib between November 2011 and December 2017. The outcomes included 2-year disease-fre
Like
Comment
Share
